Dr. Jain is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Philadelphia, PA 19111Phone+1 215-728-6900Fax+1 215-214-3779
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013- Temple University HospitalResidency, Internal Medicine, 2007 - 2010
Lewis Katz School of Medicine at Temple UniversityClass of 2007
Certifications & Licensure
PA State Medical License 2007 - 2024- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer Start of enrollment: 2013 Apr 29
- Metformin Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Start of enrollment: 2014 Mar 17
- Join now to see all
Publications & Presentations
PubMed
- 142 citationsNCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022.Deborah K Armstrong, Ronald D Alvarez, Floor J Backes, Jamie N Bakkum-Gamez, Lisa Barroilhet
Journal of the National Comprehensive Cancer Network. 2022-09-01 - 177 citationsNCCN Guidelines Insights: Ovarian Cancer, Version 1.2019.Deborah K. Armstrong, Ronald D. Alvarez, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht
Journal of the National Comprehensive Cancer Network. 2019-08-01 - 17 citationsFunctional proteomics interrogation of the kinome identifies MRCKA as a therapeutic target in high-grade serous ovarian carcinomaAlison Kurimchak, Carlos Herrera-Montávez, Jennifer Brown, Katherine J. Johnson, Valerie L. Sodi
Science Signaling. 2020-02-18
Press Mentions
Biggest Cervical Cancer Drug Advance in 20 YearsNovember 2nd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
